Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180188 | 1.00 | FPR2 (0.52) | FPR2PYGLKDM1AMAOAKMT2A | |
| SCHEMBL18180120 | 0.94 | CAPN1 (0.52) | FPR2PYGLKDM1AMAOAPOLB | |
| SCHEMBL19969115 | 0.94 | CAPN1 (0.52) | FPR2PYGLKDM1AMAOAPOLB | |
| SCHEMBL18180118 | 0.93 | CNR2 (0.55) | FPR2PYGLKDM1AMAOAKMT2A | |
| SCHEMBL18180129 | 0.92 | POLB (0.55) | FPR2PYGLKDM1AMAOAKMT2A | |
| SCHEMBL19969244 | 0.92 | CNR2 (0.51) | FPR2PYGLKDM1AMAOAKMT2A | |
| SCHEMBL18180106 | 0.92 | POLB (0.55) | FPR2PYGLKDM1AMAOAKMT2A | |
| SCHEMBL18180121 | 0.92 | POLB (0.58) | FPR2PYGLKDM1AMAOAKMT2A | |
| SCHEMBL18180100 | 0.92 | POLB (0.58) | FPR2PYGLKDM1AMAOAKMT2A | |
| SCHEMBL18180102 | 0.92 | PYGL (0.49) | FPR2PYGLKDM1AMAOAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | FPR2 4717/4885PYGL 498/4885KDM1A 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.